Impact of GLP ‐1 Receptor Agonists on Alcohol‐Related Liver Disease Development and Progression in Alcohol Use Disorder
Alimentary Pharmacology & Therapeutics · 2025
DOI: 10.1111/apt.70007 ↗At a glance
Journal article in Alimentary Pharmacology & Therapeutics, 2025. Written by Chia-Chih Kuo and 5 co-authors. Institution: Department of Internal Medicine, Chi Mei Medical Center, Tainan, Taiwan. Major MEDLINE topics: Glucagon-Like Peptide-1 Receptor Agonists, Dipeptidyl-Peptidase IV Inhibitors, Diabetes Mellitus, Type 2, Alcoholism. Cited 25 times so far (Crossref); 46 references.
Topics: Sucht und Abhängigkeit
Abstract (original language)
Background and Aims Glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) have shown promise in reducing alcohol consumption, but their impact on clinical outcomes in patients with alcohol use disorder (AUD) remains unclear. We investigated the association between GLP‐1RAs and the development and progression of alcohol‐related liver disease (ArLD) in patients with AUD.
Methods
Using the TriNetX Research Network, we conducted two retrospective cohort studies comparing GLP‐1RAs versus dipeptidyl peptidase‐4 inhibitors (DPP‐4is) in patients with type 2 diabetes. The first cohort included patients with AUD but without ArLD ( n = 7132 after propensity score matching), while the second comprised patients with established ArLD ( n = 1896 after matching). Primary outcomes were incident ArLD in the AUD cohort and hepatic decompensation in the ArLD cohort.
Results
In the AUD cohort (median follow‐up: 63.2 months), GLP‐1RA users showed significantly lower risks of developing ArLD compared to DPP‐4i users (incidence rate: 6.0 vs. 8.7 per 1000 person‐years; HR: 0.62, 95% CI: 0.44–0.87, p = 0.006). GLP‐1RAs were also associated with reduced risks of all‐cause mortality (HR: 0.53, p < 0.001). In the ArLD cohort (median follow‐up: 28.2 months), GLP‐1RA users demonstrated lower risks of hepatic decompensation (incidence rate: 39.5 vs. 51.4 per 1000 person‐years; HR: 0.66, 95% CI: 0.51–0.85, p = 0.001) and all‐cause mortality (HR: 0.53, p < 0.001) compared to DPP‐4i users.
Conclusions
GLP‐1RAs were associated with reduced risks of developing and progressing ArLD in patients with AUD, suggesting potential therapeutic benefits in this population.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Internal Medicine, Chi Mei Medical Center, Tainan, Taiwan.
- Department of Physical Medicine and Rehabilitation, Chi Mei Medical Center, Tainan, Taiwan.
- School of Medicine, College of Medicine, National Sun Yat-Sen University, Kaohsiung, Taiwan.
- Department of Intensive Care Medicine, Chi Mei Medical Center, Tainan, Taiwan.
ORCID profiles: Chih-Cheng Lai
Cite
APA
Kuo, C. C., Li, C. H., Chuang, M. H., Huang, P. Y., Kuo, H. T., & Lai, C. C. (2025). Impact of GLP ‐1 Receptor Agonists on Alcohol‐Related Liver Disease Development and Progression in Alcohol Use Disorder. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.70007
Vancouver
Kuo CC, Li CH, Chuang MH, Huang PY, Kuo HT, Lai CC. Impact of GLP ‐1 Receptor Agonists on Alcohol‐Related Liver Disease Development and Progression in Alcohol Use Disorder. Alimentary Pharmacology & Therapeutics. 2025. doi:10.1111/apt.70007
BibTeX
@article{Kuo2025,
author = {Kuo, Chia-Chih and Li, Chun-Hsien and Chuang, Min-Hsiang and Huang, Po-Yu and Kuo, Hsing-Tao and Lai, Chih-Cheng},
title = {Impact of GLP ‐1 Receptor Agonists on Alcohol‐Related Liver Disease Development and Progression in Alcohol Use Disorder},
journal = {Alimentary Pharmacology & Therapeutics},
year = {2025},
doi = {10.1111/apt.70007}
}
EUVIMED